
USG’s board doesn’t have to face a challenge to the US$7 billion sale price it accepted from Gebr Knauf KG in a deal pushed by Berkshire Hathaway, a Delaware judge ruled, saying the lawsuit was doomed by a charter provision shielding USG’s directors from mismanagement claims.
“It was no secret to USG’s stockholders that the board preferred to sell USG for more,” Vice Chancellor Sam Glasscock III wrote in an 87-page Chancery Court ruling Monday, August 31, reported Bloomberg Law.
In 2018, USG agreed to be acquired by Germany’s Gebr Knauf KG for US$7 billion, capping months of deal talks between the two building-materials firms and USG’s largest investor, Warren Buffett’s Berkshire Hathaway
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas